Purchase the ATMP report at www.evernowpublishing.com

Subscribe to MedNous and get ahead in the business of medical innovation. Subscribe now.

The latest MedNous journal. Subscribe to download.

GSK reports long-term benefit of Nucala

Country: United Kingdom

A multi-year study of the asthma drug Nucala (mepolizumab) has shown the treatment to be effective in asthma control and reducing acute episodes of the disease, according to GlaxoSmithKline Plc. The company disclosed the data on 20 May at a meeting of the American Thoracic Society.

Read more

Positive Phase 3 results for Dupixent

Country: France

Dupixent (dupilumab) has delivered positive results in a Phase 3 trial involving adolescents with moderate-to-severe atopic dermatitis. The drug is already approved for the same disease in adults and is the first biologic to show a benefit in this patient group.

Read more

NOXXON gives update on cancer study

Country: Germany

Read more

AZ and Emulate in drug safety alliance

Country: United Kingdom

Read more

AZ drug for COPD fails first of two Phase 3 trials

Country: United Kingdom

Read more

Growth for Lundbeck depression drugs

Country: Denmark

Read more

Genmab more than doubles Q1 sales

Country: Denmark

Read more

FDA seeks action against stem cell clinics

Country: United States

Read more

Roche combination trial fails

Country: Switzerland

Read more

Evotec confirms double-digit growth forecast

Country: Germany

Read more

Abcam will not pursue Horizon Discovery

Country: United Kingdom

Read more

InflaRx raises $57.1 million for inflammation

Country: Germany

Read more

Looking for more?

Visit our news section for more articles.

News
Our full Mednous news archive
Appointments
Latest industry appointments
Events
A list of upcoming industry events

About Mednous

MedNous is a print publication and a website for everyone involved in medical research in Europe.

Read more

Free Article

Non-governmental drug assessments in the US, by Steven Pearson

ICERStevenDPearsonContributorArticleApil2018.pdf

Highlights of the April 2018 MedNous issue

The April 2018 MedNous features:

Latest Mednous cover
  • Business Strategy
    New approach to atrial fibrillation
    Interview with Acesion Pharma
  • Research Strategy
    How genome editing is impacting cell therapy
    By Jonathan Moore
  • Public Policy
    Non-governmental drug assessments in the US
    By Steven Pearson
  • Health Technology Assessment
    The EU prepares to legislate
    By Karen Finn
  • Business Strategy
    What Roche’s takeover of Flatiron Health really means
    By Tara Raveendran
  • Commentary
    Innate Pharma aims to regain leadership in IO
    By Robin Davison
  • Gene Therapy
    Novartis pays $8.7 billion for AveXis

The latest MedNous journal. Subscribe to download.